Oncology

Janet Espirito, PharmD, discusses real-world outcomes from a large community oncology study showing that patients with BRAF-mutated melanoma—including those with brain metastases—experienced similar benefit from frontline immune checkpoint inhibitor (ICI) therapy.

With robust pipelines, cell therapy remains the major driver for drug development.

Following robust progression-free survival indications in the phase 3 inMIND trial, the FDA granted approval to tafasitamab-cxix in combination with standard-of-care lenalidomide and rituximab for patients with relapsed or refractory follicular lymphoma.

The emergence of biomarkers plays a critical role in the growing success of treatment.

In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This single-center, descriptive, retrospective chart review identified barriers to outpatient chemotherapy use, revealing avoidable inpatient stays and highlighting targets for stewardship interventions.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

Vitamin D could offer an alternative option over hard-to-access and burdensome cancer drugs to heighten the response of chemotherapy.

Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.

The investigational blood test achieved 99% sensitivity and specificity.

Pharmacists are redefining health care by bridging clinical and economic evidence, making a real difference in patient outcomes through health economics and outcomes research (HEOR).

Pembrolizumab gains FDA approval as a groundbreaking neoadjuvant treatment for resectable locally advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Mitomycin intravesical solution is the first FDA-approved treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Biologics and biosimilars have a major role in modern medicine because of their clinical benefits and economic impact on patient care.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Significant challenges persist, particularly in low- and middle-income countries.

The approval of the tablet formulation of zanubrutinib covers all 5 approved indications of the Bruton tyrosine kinase inhibitor.

Taletrectinib demonstrated high response rates and was well tolerated among patients with ROS1+ non-small cell lung cancer (NSCLC).

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).

Asciminib shows superior tolerability over nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, enhancing treatment options and patient outcomes.